CoronaryAtlas logo
CoronaryAtlas
Sirtuin 1
Pathway / Plaque inflammation

Sirtuin 1

SIRT1protein

SIRT1 deacetylates NF-κB to suppress plaque inflammation and prothrombotic signaling, while preventing oxidized-LDL-induced endothelial dysfunction and cardiomyocyte injury.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleNF-κB inhibitor; suppresses NLRP3 and prothrombotic phenotype; cardioprotective.
Also acts inLipid entry/oxidation, Myocardial injury
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000096717

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
61
A — assay feasibility
72
E — evidence strength
15
T1DI (composite)
3
Specificity differential (R−C)-46.1
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 1
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 2
7high-demand / peri-operative stressmag 2
Coverage: 6/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 15 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.019
Open Targets association (STEMI)

Literature evidence(6)

Clinical trials(1)